At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 623 enrolled
Drug / intervention
Rifaximin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg TID in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome
In Brief
A Phase 3 clinical trial evaluating Rifaximin and Placebo for Non-Constipation Irritable Bowel Syndrome. Completed, enrolled 623 participants across 96 sites in 2 countries.
Detailed Summary
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2008
First PostedAug 2008
Primary CompletionAug 2009
Study CompletionSep 2009
TodayJul 2026
First PostedAug 11, 2008
Enrollment StartJul 1, 2008
Primary CompletionAug 1, 2009
Study CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 17.9 years ago
Interventions
Rifaximindrug
Placebodrug